BloodJClub
Human milk oligosaccharide (2'-FL) modifies the gut microbiome in children after bone marrow transplant.
Blood · · Clinical Trial, Phase II
Ramos, Langenberg + more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
Daily oral 2'-fucosyllactose (2'-FL) given from conditioning through day +30 preserves gut Shannon diversity and is linked to reduced grade II–IV acute GI GVHD (0% vs 17%) after allo-HSCT in children.
- Why it matters: After allogeneic hematopoietic stem cell transplant, gut dysbiosis increases risk for acute gastrointestinal graft-versus-host disease, and effective prebiotic strategies are needed.
- What they did: In a prospective phase 1/2 study, 70 pediatric patients received daily 2'-FL; phase 1/2 endpoints assessed safety and longitudinal microbiome diversity, with ≥60% adherence analyzed and 29 age-matched biorepository controls compared.
- The result: 2'-FL recipients maintained Shannon diversity (P = .04 vs controls) and showed higher associations of Bifidobacteria and Blautia (adjusted P < .05), alongside lower grade II–IV acute GI GVHD (P = .009) and adenovirus reactivation (P = .009) versus controls.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.